Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Himanen

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Heliyon|June 7, 2021
Ephrin-A1 and the sheddase ADAM12 are upregulated in COVID-19Rachelle Mendoza, Nayanendu Saha, Amir Momeni, et al.
Cell Reports|July 1, 2023
Integration of cancer-related genetic landscape of Eph receptors and ephrins with proteomics identifies a crosstalk between EPHB6 and EGFRGlinton Hanover, Frederick S Vizeacoumar, Sara L Banerjee, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 26, 2024
Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cellsNayanendu Saha, Sang Gyu Lee, Eeva-Christine Brockmann, et al.
Cell|November 1, 2011
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphomaElisa Oricchio, Gouri Nanjangud, Andrew L Wolfe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2023
A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer TherapyAmr El Zawily, Frederick S Vizeacoumar, Renuka Dahiya, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Heliyon|June 7, 2021
Ephrin-A1 and the sheddase ADAM12 are upregulated in COVID-19Rachelle Mendoza, Nayanendu Saha, Amir Momeni, et al.
Cell Reports|July 1, 2023
Integration of cancer-related genetic landscape of Eph receptors and ephrins with proteomics identifies a crosstalk between EPHB6 and EGFRGlinton Hanover, Frederick S Vizeacoumar, Sara L Banerjee, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 26, 2024
Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cellsNayanendu Saha, Sang Gyu Lee, Eeva-Christine Brockmann, et al.
Cell|November 1, 2011
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphomaElisa Oricchio, Gouri Nanjangud, Andrew L Wolfe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2023
A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer TherapyAmr El Zawily, Frederick S Vizeacoumar, Renuka Dahiya, et al.
Pageof 6